Trials / Unknown
UnknownNCT05759312
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
Zimberelimab Combined With Metformin in the Treatment of Recurrent Ovarian Clear Cell Carcinoma: A Pilot Study
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma.
Detailed description
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that PD-1 inhibitors may have clinical benefits for OCCC patients. This single-arm, single-center, pilot study evaluates the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zimberelimab | Zimberelimab 240mg IV every 2 weeks |
| DRUG | Metformin Hydrochloride | Metformin 2000mg PO QD |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2023-03-08
- Last updated
- 2023-03-08
Source: ClinicalTrials.gov record NCT05759312. Inclusion in this directory is not an endorsement.